XML Financial LLC Buys 8,500 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

XML Financial LLC increased its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 58.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,000 shares of the biotechnology company’s stock after acquiring an additional 8,500 shares during the quarter. XML Financial LLC’s holdings in Iovance Biotherapeutics were worth $170,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Clear Harbor Asset Management LLC boosted its position in shares of Iovance Biotherapeutics by 34.2% during the fourth quarter. Clear Harbor Asset Management LLC now owns 23,550 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 6,000 shares in the last quarter. Arkadios Wealth Advisors acquired a new stake in Iovance Biotherapeutics during the 4th quarter worth $150,000. Assenagon Asset Management S.A. bought a new position in Iovance Biotherapeutics during the fourth quarter worth about $12,927,000. Principal Financial Group Inc. grew its stake in Iovance Biotherapeutics by 59.0% in the third quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company’s stock valued at $37,872,000 after acquiring an additional 1,496,941 shares during the period. Finally, Franklin Resources Inc. increased its holdings in shares of Iovance Biotherapeutics by 9.2% in the third quarter. Franklin Resources Inc. now owns 100,229 shares of the biotechnology company’s stock worth $979,000 after acquiring an additional 8,470 shares in the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Stock Up 3.3 %

Shares of IOVA stock opened at $6.19 on Friday. Iovance Biotherapeutics, Inc. has a 12 month low of $5.57 and a 12 month high of $18.33. The company’s fifty day simple moving average is $7.67 and its 200-day simple moving average is $9.09. The firm has a market cap of $1.89 billion, a PE ratio of -4.15 and a beta of 0.57.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.03. The firm had revenue of $58.56 million for the quarter, compared to analysts’ expectations of $53.54 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. During the same period in the previous year, the firm posted ($0.46) EPS. On average, equities analysts predict that Iovance Biotherapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Insider Activity at Iovance Biotherapeutics

In other news, Director Ryan D. Maynard sold 50,000 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $10.06, for a total value of $503,000.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $75,450. This represents a 86.96 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 12.10% of the company’s stock.

Analyst Upgrades and Downgrades

IOVA has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of Iovance Biotherapeutics in a report on Wednesday, November 6th. UBS Group initiated coverage on shares of Iovance Biotherapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $17.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $23.00.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.